Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SEfiledCriticalBioNTech SE
Publication of CL2023000941A1publicationCriticalpatent/CL2023000941A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente divulgación se refiere a métodos para preparar partículas de lipoplexo de RNA para suministrar RNA a tejidos diana después de la administración parenteral, en particular después de la administración intravenosa, y composiciones que comprenden tales partículas de lipoplexo de RNA. La presente divulgación también se refiere a métodos que permiten preparar partículas de lipoplexo de RNA de una manera que cumple con las GMP industriales. Además, la presente divulgación se refiere a métodos y composiciones para almacenar partículas de lipoplexo de RNA sin pérdida sustancial de la calidad del producto y, en particular, sin pérdida sustancial de la actividad del RNA.The present disclosure relates to methods for preparing RNA lipoplex particles for delivering RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods that allow RNA lipoplex particles to be prepared in a manner that complies with industrial GMP. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of product quality and, in particular, without substantial loss of RNA activity.
CL2023000941A2020-10-012023-03-30
Preparation and storage of liposomal RNA formulations suitable for therapy
CL2023000941A1
(en)
Preparation created from an in vitro culture of dedifferentiated, non-elicited cells of the argania tree, use thereof for treating skin ageing, inflammation and scarring, and production thereof
Product comprising a food body composed of a food component and an infusion component that contains bad todextrin in a concentration of 5 to 65% with respect to the body of the food; food product; method to produce an infused food body; and infusion formulations.